Graham Ball is Professor of Bioinformatics at Nottingham Trent University (NTU) and founder and Chief Technical Officer of Bioinformatics for CompanDX Ltd. He has been involved in the development and validation of bioinformatic algorithms using Artificial Neural Networks for biomarker discovery the last 18 years. After a PhD (UN funded) and a Post Doc modelling environmental interactions with ANNs at NTU, in 2000 he shifted the focus of his analysis to proteomic and genomic data searching for proteins and genes associated with cancer and other diseases. His current research interests are directed at the classification and characterisation of biological systems including diagnostic and classification modelling of microbial pathogens, cancer clinical pathology, allergic responses and viral diseases through the use of ANNs and other machine learning techniques.
Michael Bereman joined North Carolina State University in August 2013 as a Chancellor’s Faculty Excellence Program cluster hire in environmental science. He is an Assistant Professor in the Department of Biological Sciences and a member of the Center for Human Health and the Environment (CHHE). Dr. Bereman is a leader in the field of bioanalytical mass spectrometry and his research spans key areas in the fields of analytical chemistry, proteomics, biology, statistics, bioinformatics and technology development. His efforts focus on the continued improvement in technology with targeted applications in two main areas: 1) Development of analytical assays to quantify the degree of overall environmental exposure using existing, modified and novel targets in biological fluids; and 2) the elucidation of the impact of various environmental exposures on the etiology of diseases using both human specimens and animal models. Dr. Bereman’s ultimate goal is to develop a comprehensive understanding of the effects of the local environment on human biology such that therapeutic targets could be discovered and disease risk mitigated by limiting exposure. Michael received his PhD from North Carolina State University in chemistry and performed his post- doctoral studies at the University of Washington in Department of Genome Sciences where he was an NIH Genome Training Fellow. In 2012, he was named by the editors of Analytical and Bioanalytical Chemistry a top young investigator.
Paul Cutler has been Head of Mass Spectrometry within Translational Technologies and Bionformatics at Roche Pharmaceuticals since 2009. From 1993&endash;2009 Dr. Cutler held various roles of increasing responsibility in the areas of proteomics and bioanalysis at GlaxoSmithKline. From 1998&endash;2003 he was a Principal Scientist at Celltech (now part of UCB) and before this was at Unipath (part of the Unilver Group). Dr. Cutler gained his first degree in Biochemistry from the Univeristy of Liverpool and a PhD from the University of Aston (both in the UK).
Jeanette Eckel-Passow is an Associate Professor of Biostatistics at Mayo Clinic. Her research interests entail developing statistical methods for genome-wide omics data. She has developed statistical methods for normalization and analysis of microarray data, protein mass- spectrometry data, array comparative genomic hybridization data and copy number variation data obtained from whole-genome SNP chips. More recently, Dr. Eckel-Passow’s research has shifted to next generation sequencing data. Her overall goal is to apply statistical methods to genome-wide omics data for the identification of cancer molecular biomarkers and she is actively participating in genomic studies related to clear cell renal cell carcinoma (ccRCC), brain cancer, breast cancer and prostate cancer.
Peter Findeisen is an Associate Professor at the Institute of Clinical Chemistry of the Medical Faculty Mannheim of the University of Heidelberg. His current research efforts are focused on investigating the role of protease-deregulation in malignant disease. His main research objective is the identification of new biomarkers to improve laboratory based diagnosis of tumors. His group has developed several MS-based assays that allow the monitoring of tumor associated proteolytic activity in clinical specimens like serum and plasma. Furthermore he is head of the proteomics core facility of the Medical Faculty Mannheim of the University of Heidelberg. He studied pharmacy and medicine and works as consultant at the University Hospital Mannheim since 2008. He is a reviewer for numerous international Journals and has served as organizer and session chair for several conferences.
Sebastien Gallien is a Research Scientist in the laboratory of Dr. Bruno Domon (Luxembourg Clinical Proteomics Center) at CRP-Sante, Luxembourg. He received his PhD degree in analytical chemistry from the University of Strasbourg at the Bioorganic Mass Spectrometry Laboratory in 2009 under the supervision of Dr. Alain Van Dorsselaer. He was then a postdoctoral fellow for two years at the Luxembourg Clinical Proteomics Center. His current research is focused on technology and methodology developments for targeted quantitative proteomics with emphasis on clinical applications.
Hendrik Neubert is an Associate Research Fellow and quantitative bioanalytical discipline leader in Pfizer’s Pharmacokinetics Dynamics and Metabolism department in Andover/Cambridge MA. He heads a bioanalytical group that develops and implements innovative quantitative assays based on mass spectrometry and flow cytometry for pharmacodynamic biomarkers and proteins targeted by biologics. The work spans across several disease areas and includes a close partnership with PK/PD modelers to define biological systems parameter that contribute for example to validation of the therapeutic target and rationalizing the dosing regimen of the therapeutic. Before moving to the US in 2010, Hendrik joined Pfizer in the United Kingdom in 2004 as a Manager in Clinical Pharmacology working in the field of clinical proteomics and targeted mass spectrometry assays for protein biomarkers, biologics and immunogenicity. Prior to joining Pfizer, Hendrik held a postdoctoral position at the Drug Control Centre at King’s College London. He received his PhD from Kings College London in 2002 and prior to that his Pharmacy diploma from ETH Zurich in 1997.
Jean-Daniel Tissot specialized in internal medicine, hematology and transfusion medicine. He is chief physician and director of the Service régional vaudois de transfusion sanguine, in Epalinges, Switzerland. He is full professor of hematology at the Faculty of Biology and Medicine of the University of Lausanne. His main research interests deal with iron deficiency in blood donors, mainly in the absence of anemia, ethical issues in blood transfusion and with proteomic and functional studies of blood products (storage lesions). He authored about 160 articles or book chapters, and he recently co edited a book entitled “Le Sang; Arts - Sciences - Vie”, published by Favre Editions, Lausanne, Paris.